1-3 of 3
Markus Vähä-Koskela, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2743.
https://doi.org/10.1182/blood-2018-99-116391
Published: 2018
Journal Articles

Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

Mahesh Tambe, PhD, Ella Karjalainen, MSc, Markus Vaha-Koskela, PhD, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Krister Wennerberg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2210.
https://doi.org/10.1182/blood-2018-99-118289
Published: 2018
Journal Articles

Dasatinib-Induced Reduction of Tumor Growth Is Accompanied By the Changes in the Immune Profile in a Melanoma B16.OVA Mouse Model

Mette Matilda Ilander, MSc, Can Hekim, PhD, Markus Vähä-Koskela, PhD, Paula Savola, Siri Tähtinen, MSc, Leena Saikko, Akseli Hemminki, MDPhD, Panu Kovanen, MDPhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MDPhD
Journal: Blood
Blood (2014) 124 (21): 1408.
https://doi.org/10.1182/blood.V124.21.1408.1408
Published: 2014